Combinations of penciclovir (PCV) with other antiviral agents (acyclovir, ACV; ganciclovir, GCV; foscarnet, PFA; azido-thymidine, AZn or with human interferons (HuIFN-a,I3,'Y) were tested for inhibitory activity against herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2) in cell culture. The antiviral interactions observed between combinations of PCV with ACV or GCV were purely additive. Combinations of PCV with HulFNs demonstrated highly synergistic anti-herpesvirus activity; some synergy was also detected between PCV and PFA against HSV-1. High concentrations of AZT inhibited the antiviral activity of PCV; this antagonism was competitive. In more detailed studies it was demonstrated that high concentrations of AZT also inhibited the antiviral activity of ACV, and that ACV was more sensitive to this antagonism than PCV. It was concluded that the antagonism was unlikely to have clinical significance.
Introduction
The acyclic guanine derivative penciclovir (9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine, BRL 39123, PCV) has potent activity against several human herpesviruses both in cell culture (Tippie et al., 1984; Larsson et al., 1986; McCoss et al., 1986; Boyd et al., 1987) and in animal models (Boyd et al., 1988) . The compound is currently being evaluated in clinical trials against herpes simplex virus (HSV) and varicella zoster virus (VZV) infections.
It is possible that during the treatment of human herpesvirus infections, PCV may be used in combination with other antiviral agents. To determine whether synergy or antagonism between such agents and PCV could occur, it was necessary to assess the antiviral activities of the compound combinations in cell culture. The antiherpesvirus compounds acyclovir (ACV) , ,ganciclovir (GCV) , and foscarnet (PFA) and the anti-retrovirus compound azido-thymidine (AZ1), were included in this study.
Combinations of the acyclic nucleosides ACV or GCV, with human interferons (HuIFN), have shown synergy against HSV in cell culture (Levin and Leary, 1981; Stanwick et aI., 1981; Eppstein and Marsh, 1984) . However, other nucleosides with activity in cell culture . against HSV do not always share this property, for example, combinations of adenine arabinoside and HuIFN-13 were not synergistic against HSV-2 in cell culture (Bryson and Kronenberg, 1977) , trifluorothymidine (TF1) and HuIFN-13 did not show synergy against cytomegalovirus (Spector et aI., 1983) , and neither bromovinyldeoxyu-· ridine nor TFT were synergistic with IFN-a2 (Taylor et al., 1991) . Accordingly, an investigation into whether or not PCV synergizes with HulFN in cell culture was necessary, particularly because antiviral agents which have this property may have greater activity in vivo than expected due to interactions with endogenous IFN produced during viral infection. It may also be possible to improve the efficacy of such compounds further by co-administration of exogenous IFN, particularly in situations where IFN production is deficient. Finally, in addition to the investigation into the antiviral activity of various compound and HulFN combinations, the effects of these combinations on the proliferation of uninfected cells were also assessed.
Results

Antiviral efficacy of compounds or HulFN alone
The fifty per cent inhibitory concentration (IC so ) values of each of the antiviral agents alone, against HSV-1 or HSV-2 are presented in Table 1 and dose response curves are shown in Figs 1-6. PCV,ACV, and GCVall demonstrated good antiviral activity against both HSV-1 and HSV-2. PFA showed some activity against HSV-2 (IC so = 28 J.Lg mr'), . , PCV alone {1JLg ml-1 }; 0, ACV in combination with 1 JLg ml-2 PCV; ---, predicted values for combinations of ACV and PCV {see text for explanation}. PCV alone (1 fl9 ml-1 ) ; 0, PFA in combination with 1 flg mr' PCV; ---, predicted values for combinations of PFA and PCV (see text for explanation). Each point is the mean (± S.D.) of four determinations. Leary, 1981; Stanwick et sl., 1981; Eppstein and Marsh, 1984) .
Activity of PCV in combination with other antiviral compounds
The results of plaque reduction assays in which ACV, GCV, PFA, or AZT were tested either alone or in combin- alone; 0, 0.1 ,.,,9 rnr ' AZT; 6, 1 ,.,,9 rnr': ,.., 10,.,,9mr' AZT; 0, 100,.,,9 ml? AZT. Each point is the mean of two determinations.
predicted for additive activity that counts would only be reduced to 81% of the virus control level.
When combinations of 1 [Lg rnr' PCV were tested with various concentrations of AZT against HSV-1 or HSV-2, some antagonism was evident ( Fig. 4 ). This effect was particularly pronounced against HSV-1. At concentrations of 10 [Lg rnl" AZT, the antiviral activity of 1 [Lg mr ' PCV was totally inhibited.
There was no evidence of altered cytotoxicity when PCV was combined with either ACV, GCV, PFA, or AZT at the same concentrations used in the plaque reduction assays. In all cases the observed cytotoxicity of the drug combination (determined by 3H-thymidine incorporation) was equal to the predicted cytotoxicity of the combination (data not shown).
Further investigation of the inhibition of antiviral activity byAZT
As AZT appeared to antagonize the anti-herpesvirus activity of PCV, further studies were performed in which AZT was combined with either PCV or ACV, and testedtor activity against HSV-1 and HSV-2. It was demonstrated that high concentrations of AZT blocked the anti-herpesvirus activity of both PCV and ACV. The extent of inhibition by AZT was directly related to the concentration of AZT present, with increasing concentrations of AZT causing a progressive decrease in the activities of PCV and ACV ( 
Reversal of activity of PCV and ACV by deoxythymidine
Both PCV and ACV were antagonized by deoxythymidine in a virus yield experiment (Table 3 ). However, ACV was more susceptible to lower concentrations of deoxythymidine than PCV. For example, with deoxythymidine at Virus titre" (Iog, o pfu 0.1 rnr') The data in Fig. 6 relate to combinations of HulFN and 0.3fL9 mr' PCV, since 0.3fL9 mr' was the lowest concentration of PCV in this series of experiments giving a significant reduction in plaque numbers. At higher concentrations of PCV, synergy with HulFN still occurred, but was less obvious because of the greater activity of PCV alone.
There was no evidence of cytotoxicity when PCV was combined with HuIFN-cx, f3 or 'Y. In each case the concentration of compound required to inhibit 3H-thymidine incorporation by 50% was greater than the maximum concentration tested (3fLg mr' PCV, 1000 IU mr" HuIFN;
data not shown).
Activity of PCV in combination with HulFN
Synergy between PCV and each of the three types of HulFN was demonstrated against both HSV-1 and HSV-2 by the plaque reduction assay (Fig. 6) . In all cases, the observed reduction in plaque numbers after treatment with the combination was substantially greater than the product of the plaque reduction caused by either treatment alone, and increased in proportion to the concentration of HuIFN. Combinations of PCVwith HuIFN-cx showed the greatest synergy. For example, to reduce HSV-1 or HSV-2 plaque formation by >90 per cent in the presence of 0.3 fL9 rnr' of PCV, 10 IU mr' and 300 IU mr' HuIFN-cx respectively were required, whereas to achieve a similar effect with HuIFN-f3, higher concentrations were required (>300IU rnr' for HSV-1; >10001U rnr' for HSV-2).
Although dose related synergy was also seen with combinations of PCV and HuIFN-'Y, the effect was generally less pronounced than with either HuIFN-cx or HuIFN-f3. For each HulFN tested, the synergy was more pronounced against HSV-1 than HSV-2. increased to levels above those detected in untreated virus control monolayers.
The IC 50 values against HSV-1 and HSV-2 for PCV and ACV in the presence of various concentrations of AZT were also calculated (Table2). Several points can be made following examination of these values. First, the extent of antagonism of PCV or ACV activities by AZT was more pronounced against HSV-1 than HSV-2. Second, analysis of the data indicated that ACV was more sensitive than PCVto antagonism by AZT; for example with HSV-1, when AZTwas present at a concentration of 10 fL9 rnrl.the IC 50 of ACV was increased 12 fold, while the IC 50 of pev was increased only 4 fold. It is important to note that AZT concentrations of 30 and 10 fL9 mr' would not be achieved within the bloodstream of AZT-treated patients, thus only concentrations of 3 fL9 ml" AZT or less may have clinical relevance. (Yarchoan et al., 1986) 0.2 fL9 mr' the yield of virus from cultures co-treated with ACV at 3 fL9 rnr " increased 12 fold relative to the control cultures treated with ACV alone. The corresponding loss in activity for PCV was reflected by a 2 fold increase in virus yield.
Discussion
The results reported in this study indicate that combinations of PCV with either ACV or GCV interact in a purely additive fashion with respect to antiviral activity. In contrast, combinations of PCV with PFA did demonstrate slight synergy against HSV-1, although not against HSV-2. In a similar study to the one performed here, it Was reported that GCV was highly synergistic with PFA, but that PFA showed no synergy with ACV (Smith et al., 1982) . It was proposed that the synergy between PFA and GCV occurred as a result of the two drugs interacting with different regions of the viral DNA polymerase. This suggestion was investigated in more depth by Crumpacker et al. (1984) who studied resistance patterns to selected antiviral agents and physically mapped the locations ot resistance mutations within the DNA polymerase coding sequence. Mutations for phosphonoacetic acid (PM) and ACV resistance were closely linked on the same 2.6 kbp region of HSV-1 DNA, perhaps explaining why ACV and PFA were not synergistic in the study reported by Smith et al. (1982) . In contrast, the site conferrillg GCV resistance was distant from that for PM, thus supporting the theory thatthe observed GCV and PFAsynergy may be due to the drugs interacting with different regions of the HSV DNA polymerase. The fact that, in the present study, PCV shows slight synergy with PFA against HSV-1 suggests that the PCV triphosphate binding site may not be tightly Iinkedto the PFA binding site on the HSV-1 DNA polymerase.
It was demonstrated in this study that AZT blocked the activity against HSV of both PCV and ACV; the results were indicative of competitive antagonism. PCV and ACV are substrates for the HSV thymidine kinase and the monophosphate derivatives of PCV and ACV are substrates for cellular kinases. It is possible that AZT is also a substrate for HSV thymidine kinase and it has been demonstrated that AZT is phosphorylated by cellular kinases (Koshida et al., 1989) . Thus, the observed antagonism may arise from direct competition between either ACV or PCV and AZT for the thymidine kinase binding site or between the monophosphates and a cellular kinase binding site. Evidence from additional studies support this form of antagonism; PCV and ACV activities were also competitively antagonized by the addition of the natural substrate for thymidine kinase, deoxythymidine (fable 3). ACV was more sensitive than PCV to antagonism by both Interactions of penciclovir with antiviral agents 91 AZT and deoxythymidine, although in the latter case, this may be partly due to the greater activity of PCV in the absence of deoxythymidine.
In a recent study conducted by Yang et al. (1990) it was noted that AZT also had an antagonistic effect on the activity of GCV against guinea-pig cytomegalovirus (GPCMV) in cell culture. This antagonistic effect was only evident when the ratio of AZT to GCV was high; at lower ratios the combinations exhibited a purely additive antiviral effect. The authors did not investigate the mechanism of antagonism but they also speculated that AZT, or a phosphorylated derivative of AZT, may competitively inhibit the phosphorylation of GCV by cellular kinases. An antagonistic interaction between AZT and GCV against human cytomegalovirus was also recently described (Tlan etal.,1991) .
Caution should be exercised in extrapolating the results of this cell culture study to the use of AZT in combination with PCV or ACV in humans. Following either oral administration or intravenous infusion of a typical dose of AZT to humans, peak plasma concentrations (C max) of AZT were in the order of 2 to 3 fL9 ml-1 (Retrovir, Product Monograph; Yarchoan et aI., 1986) . It is therefore inconceivable that the highest concentrations of AZT used in this cell culture study (30or 100 fL9 ml"") would ever be achieved in humans, and unlikely that concentrations of 10 fL9 rnr' would be achieved. It is important to note that ACV is recommended for treating herpesvirus infections in patients with AIDS (Griffiths, 1990) , and that antagonism between ACV and AZT in humans has not been documented. It is probable that PCV will also be used in this group of patients, and, because the antagonism of PCV by AZT is less marked than that of ACV, particularly at higher AZT concentrations, antagonism in humans is even less likely to be a problem. At concentrations of AZT up to 10 fL9 ml-1 the IC so values of PCV for HSV-1 ranged from 0.5 fL9 ml-1 to 2.8 fL9 mr' and for HSV-2 from 1.4 fLg mr' to 2.1 fLg mr'. These AZT concentrations are unlikely to compromise the anti-herpesvirus activity of PCV in AIDS patients because the mean C max for PCV in healthy male subjects following a 500 mg oral dose of famciclovir was 3.46fL9 ml" ± 0.79fL9 rnl" (Fowles et al., 1990) which would encompass the IC so values. Cell culture studies have also been performed to investigate interactions between AZT and either PCV or ACV against human immunodeficiency virus type 1 (HIV-1) using the M8166 cell line. No antagonism or synergy was observed with either compound (data not shown). In contrast, it has been reported that GCV antagonized the activity of AZT against HIV-1 in cell culture at concentrations which can be achieved in patients (Medina et aI., 1991) .
PCV interacts synergistically with HuIFN, as has also been reported for two other acyclic purine nucleosides, ACV and GCV (Levin and Leary, 1981; Stanwick et al., 1981; Eppstein and Marsh, 1984) , although the mechanism of this synergistic antiviral activity has not been fully elucidated. However, it was recently reported that treatment of HSV-1-infected cells with HulFN reduced the pool size of endogenous deoxyribonucleoside (dNTP) triphosphates relative to untreated HSV-1-infected cultures (O'Brien et al., 1990) . It was therefore suggested that the increased ACV-TP to dNTP ratio would contribute to the antiviral synergy seen in cultures treated with combinations of ACV and HuIFN-u. A similar mechanism may operate with combinations of PCV and HuIFN.
Studies have not yet been performed to investigate whether PCV and IFN interact synergistically in vivo. However, combinations of ACV with HuIFN-u (Connell et al., 1985) or GCV with HuIFN-u (Fraser-Smith et aI., 1984) were synergistic in HSV-infected mice. Moreover, ACV together with HuIFN-u was significantly more active in patients with herpes keratitis than was treatment with ACV alone (Meurs and Van Bijsterveld, 1985) .Thus, by virtue of activity in cell cuture, we predict that PCV and HulFN will also interact synergistically in vivo. Although HuIFN-u in combination with PCV was more synergistic than either IFN-13 or IFN-'Y in these cell culture studies, it is possible that HuIFN-'Y could show greater synergy with PCV in vivo because of its immunoregulatory properties (Bonnem and Oldham, 1987) . For example, murine IFN-'Y combined with GCV had greater activity against HSV-2 in mice than was predicted from the activity of the combination in cell culture (Fraser-Smith et al., 1985) .
Materials and Experimental procedures
Test compounds
PCV was synthesized within the chemical laboratories of Smith-Kline Beecham Pharmaceuticals, Epsom, UK (Harnden and Jarvest, 1985) as were ACV and GCV. PFA was a gift from Astra l.akernedal AB, Sodertaljle, Sweden. AZT was purchased from Sigma Chemical Company Ltd (Poole, UK).
Human interferons
The interferons were obtained from the following sources; HuIFN-«-nt (Weliferon™, The Wellcome Foundation Ltd, London UK), HuIFN-13 (Fiblaferon RS, Rentschler Group, Laupheim, West Germany), HuIFN-'Y4A used for the antiviral assays (AMGEN Biologicals, California, USA) and HuIFN-'Y used for the cytotoxicity assays (Sigma Chemical Company Ltd, Poole, UK).
Plaque reduction assays
Confluent monolayers of MRC-S cells were infected with S0-100 pfu of HSV-1 (strain SC16) or HSV-2 (strain MS) as previously described (Boyd et al., 1987) . The compounds and interferons were tested alone in dose response experiments to establish their individual activities. Subsequently, PCV was tested in combination with each of the others using a checkerboard arrangement of concentrations. While PCV was tested in a range of concentrations within each combination, a single concentration was chosen to illustrate interactive effects, 1 fL9 rnr' in Figs 1-4, and 0.3 fL9 rnl:" in Fig. 6 . In addition, for comparative purposes, ACV was tested in combination with AZT in a series of experiments. In all experiments, compounds or HulFN were added 1 h after infection.
The fractional product method was used to assess whether the interaction between compounds was synergistic, additive, or antagonistic, by comparing the observed percentage of control plaque number due to the combination with the predicted value. The latter was calculated as follows: The observed fraction is the number of plaques for the test compound divided by the number of plaques in the untreated control. The derived figures were plotted graphically as Shown in Figs 1-6. Additive interaction occurred if the curves from the observed values and the predicted values were coincident. Synergistic interaction occurred if the observed values were lower than the predicted values and antagonism occurred if the observed values were higher than the predicted values (Bryson and Kronenberg, 1977; Koshida et al., 1989; Lobe et al., 1991; Stanwick et al., 1981) .
Virus yield assays
Confluent monolayers of MRC-S cells were infected with HSV-1 (strain SC16) at approximately 1 pfu cell-1 and treated with PCV and ACV alone and in combination with deoxythymidine. Compounds were added 1 h after virus inoculation and virus yields were measured 23 h later. All combinations were performed in triplicate. The supernatants from replicate cultures were pooled and titrated in duplicate on Vero cells.
Cytotoxicity assays
To exclude the possibility that any non-additive 'interaction between compounds was due toaltered cytotoxicity of the combination, the effect of compounds either alone or in combination, on MRC-S cell replication were assessed. Microwellplates (Nunc, Roskilde, Denmark) were seeded with MRC-S cells (10 4 cellswell':") in Eagle's Minimal Essential Medium.containing 10% foetal calf serum. Immediately after seeding, compounds were added to the cells at the same concentrations as used within the plaque reduction assays. Following 72 h incubation at 37"C (equivalent to approximately 3 population doublings), each culture was pulse-labelled for Sh with O.S fLCi of [6-3H]thymidine (Amersham International pic, Aylesbury, UK). The cells were harvested onto glassfibre filtermats and the amount of [6-3H]thymidine incorporated into cellular DNA measured using an LKB Beta Plate Counter (Potter et al., 1987) . Data were examined for evidence of synergy or antagonism as described for the plaque assays.
